Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes

Diabetes and Metabolism

Volumn 34, Issue SUPPL. 2, 2008, Pages

  Gautier, J F ^a,b   Choukem, S P ^a   Girard, J ^c  

^a SAINT LOUIS HOSPITAL   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c INSTITUT COCHIN   (France)

Author keywords

Glucagon like peptide 1; Incretin hormones; Insulin; Type 2 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN; INSULIN; TRANSCRIPTION FACTOR 7 LIKE 2;

ARTICLE; CELLULAR DISTRIBUTION; DIET RESTRICTION; ENTEROENDOCRINE CELL; GLUCAGON RELEASE; GLUCOSE INTAKE; HORMONAL REGULATION; HORMONE RELEASE; HUMAN; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INSULIN RESPONSE; KILLER CELL; L CELL; NEUROMODULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS FUNCTION; RECEPTOR BINDING; SMALL INTESTINE; STOMACH ACID SECRETION; STOMACH EMPTYING;

ANIMALS; DIABETES MELLITUS, TYPE 2; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; INSULIN; INSULIN-SECRETING CELLS; KILLER CELLS; PROGLUCAGON;

EID: 47649095004     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(08)73397-4     Document Type: Article

References (58)

1. Moore B. On the treatment of Diabetus mellitus by acid extract of Duodenal Mucous Membrane. Biochem J 1 (1906) 28-38
2. Unger R.H., and Eisentraut A.M. Entero-insular axis. Arch Intern Med 123 (1969) 261-266
3. Creutzfeldt W., and Ebert R. New developments in the incretin concept. Diabetologia 28 (1985) 565-573
4. Gutniak M., Ørskov C., Holst J.J., Ahrén B., and Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326 (1992) 1316-1322
5. Nathan D.M., Schreiber E., Fogel H., Mojsov S., and Habener J.F. Insulinotropic action of glucagons-like peptide-I-(7-37) in diabetic and nondiabetic subjects. Diabetes Care 15 (1992) 270-276
6. Nauck M.A., Kleine N., Ørskov C., Holst J.J., Willms B., and Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagons-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36 (1993) 741-744
7. Egan J.M., Bulotta A., Hui H., and Perfetti R. GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells. Diabetes Metab Res Rev 19 (2003) 115-123
8. Fehmann H.C., Göke R., and Göke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr Rev 16 (1995) 390-410
9. Baggio L.L., and Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 132 (2007) 2131-2157
10. Margolskee R.F., Dyer J., Kokrashvili Z., et al. T1R3 and gustducin in gut sense sugars to regulate expression of Na+ -glucose cotransporter 1. Proc Natl Acad Sci USA 104 (2007) 15075-15080
11. Jang H.J., Kokrashvili Z., Theodorakis M.J., et al. Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1. Proc Natl Acad Sci USA 104 (2007) 15069-15074
12. D'Alessio D., Lu W., Sun W., et al. Fasting and postprandial concentrations of GLP-1 in intestinal lymph and portal plasma: evidence for selective release of GLP-1 in the lymph system. Am J Physiol Regul Integr Comp Physiol 293 (2007) R2163-R2169
13. Hansen L., Deacon C.F., Ørskov C., and Holst J.J. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 140 (1999) 5356-5363
14. Mentlein R. Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides. Regul Pept 85 (1999) 9-24
15. Andersen D.K., Elahi D., Brown J.C., Tobin J.D., and Andres R. Oral glucose augmentation of insulin secretion. Interactions of gastric inhibitory polypeptide with ambient glucose and insulin levels. J Clin Invest 62 (1978) 152-161
16. Dupré J., Ross S.A., Watson D., and Brown J.C. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 37 (1973) 826-828
17. Vilsbøll T., and Holst J.J. Incretins, insulin secretion and Type 2 diabetes mellitus. Diabetologia 47 (2004) 357-366
18. Miyawaki K., Yamada Y., Yano H., et al. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide knockout mice. Proc Natl Acad Sci USA 96 (1999) 14843-14847
19. Preitner F., Ibberson M., Franklin I., et al. Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors. J Clin Invest 113 (2004) 635-645
20. Yip R.G., Boylan M.O., Kieffer T.J., and Wolfe M.M. Functional GIP receptors are present on adipocytes. Endocrinology 139 (1998) 4004-4007
21. Yip R.G., and Wolfe M.M. GIP biology and fat metabolism. Life Sci 66 (2000) 91-103
22. Trumper A., Trumper K., Trusheim H., Arnold R., Göke B., and Horsch D. Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. Mol Endocrinol 15 (2001) 1559-1570
23. Ørskov C., Wettergren A., and Holst J.J. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol 31 (1996) 665-670
24. Kreymann B., Williams G., Ghatei M.A., and Bloom S.R. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2 (1987) 1300-1304
25. Nauck M.A., Bartels E., Ørskov C., Ebert R., and Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 76 (1993) 912-917
26. Nauck M., Niedereichholtz U., Ettler R., et al. Glucagon-like peptide-1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol Endocrinol Metab 273 (1997) E981-E988
27. Holst J.J. Glucagon-like peptide-1: from extract to agent. The Claude Bernard lecture, 2005. Diabetologia 49 (2006) 253-260
28. Creutzfeldt W.O., Kleine N., Willms B., Ørskov C., Holst J.J., and Nauck M.A. Glucagonostatic actions and reduction of fasting hyperglycaemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care 19 (1996) 580-586
29. Nauck M.A., Heimesaat M.M., Behle K., et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycaemia clamp experiments in healthy volunteers. J Clin Endocrinol Metab 87 (2002) 1239-1246
30. Xu G., Kaneto H., Lopez-Avalos M., Weir G., and Bonner-Weir S. GLP-1/exendin-4 facilitates β-cell neogenesis in rat and human pancreatic ducts. Diabetes Res Clin Pract 73 (2006) 107-110
31. Buteau J., El-Assaad W., Rhodes C.J., Rosenberg L., Joly E., and Prentki M. Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 47 (2004) 806-815
32. Yusta B., Baggio L.L., Estall J.L., et al. GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress. Cell Metab 4 (2006) 391-406
33. van Dijk G., and Thiele T.E. Glucagon-like peptide-1 (7-36) amide: a central regulator of satiety and interoceptive stress. Neuropeptides 33 (1999) 406-414
34. Meier J.J., Gallwitz B., Schmidt W.E., and Nauck M.A. Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives. Eur J Pharmacol 440 (2002) 269-279
35. Flint A., Raben A., Astrup A., and Holst J.J. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101 (1998) 515-520
36. Gutzwiller J.P., Drewe J., Göke B., et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 276 (1999) R1541-R1544
37. Näslund E., Barkeling B., King N., et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 23 (1999) 304-311
38. Zander M., Madsbad S., Madsen J.L., and Holst J.J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 359 (2002) 824-830
39. Nyström T., Gutniak M.K., Zhang Q., et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 287 (2004) E1209-E1215
40. Bose A.K., Mocanu M.M., Carr R.D., Brand C.L., and Yellon D.M. Glucagonlike peptide 1 (GLP-1) can directly protect the heart against ischemia/reperfusion injury. Diabetes 54 (2005) 146-151
41. Nikolaidis L., Elahi D., Shen Y., and Shannon R. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves ventricular performance in conscious bdogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 289 (2005) H2401-H2408
42. Yamada C., Yamada Y., Tsukiyama K., et al. The murine glucagonlike Peptide-1 receptor is essential for control of bone resorption. Endocrinology 149 (2008) 574-579
43. Meier J.J., Gethmann A., Götze O., et al. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia 49 (2006) 452-458
44. Knauf C., Cani P.D., Perrin C., et al. Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest 115 (2005) 3554-3563
45. Lerche S., Brock B., Rungby J., et al. Glucagon-like-peptide-1 inhibits blood-brain glucose transfer in humans. Diabetes (2007) Nov 8 [Epub ahead of print]
46. Knop F.K., Vilsbøll T., Højberg P.V., et al. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?. Diabetes 56 (2007) 1951-1959
47. Nauck M., Stockmann F., Ebert R., and Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29 (1986) 46-52
48. Vilsbøll T., Krarup T., Deacon C.F., Madsbad S., and Holst J.J. Reduced postprandial concentrations of intact biologically active glucagons-like peptide 1 in type 2 diabetic patients. Diabetes 50 (2001) 609-613
49. Jones I.R., Owens D.R., Luzio S., Williams S., and Hayes T.M. The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 32 (1989) 668-677
50. Toft-Nielsen M.B., Damholt M.B., Madsbad S., et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86 (2001) 3717-3723
51. Nauck M.A., Heimesaat M.M., Ørskov C., Holst J.J., Ebert R., and Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91 (1993) 301-307
52. Willms B., Werner J., Holst J.J., Orskov C., Creutzfeldt W., and Nauck M.A. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 81 (1996) 327-332
53. Cauchi S., El Achhab Y., Choquet H., et al. TCF7L2 is reproducibly associated with type 2 diabetes in various ethnic groups: a global meta-analysis. J Mol Med 85 (2007) 777-782
54. Florez J.C., Jablonski K.A., Bayley N., Pollin T.I., de Bakker P.I., Shuldiner A.R., et al. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 355 (2006) 241-250
55. Grant S.F., Thorleifsson G., Reynisdottir I., et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 38 (2006) 320-323
56. Lyssenko V., Lupi R., Marchetti P., et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 117 (2007) 2155-2163
57. Schäfer S.A., Tschritter O., Machicao F., et al. Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. Diabetologia 50 (2007) 2443-2450
58. Shu L., Sauter N.S., Schulthess F.T., Matveyenko A.V., Oberholzer J., and Maedler K. TCF7L2 regulates β-cell survival and function in human pancreatic islets. Diabetes (2007) Dec 10 [Epub ahead of print]